An article from
Emerging biotech
The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.
Published July 29, 2026
Getty Images
Caldera, Vidya add to recent flurry of biotech mergers
The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.
TL;DRAI
Caldera and Vidya merged with public biotech firms, raising $478M for drug candidates in inflammatory bowel disease and multiple sclerosis. Reverse mergers replace IPO for biotech market access; signals M&A consolidation trend for clinical-stage companies.
423 words~2 min read
